ClinicalTrials.gg
Active, not recruitingNCT05362773Updated Jul 28, 2026

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

A Phase 1 interventional study of MGD024 in Leukemia, Acute Myeloid, Myelodysplastic Syndromes and Classical Hodgkin Lymphoma, sponsored by MacroGenics. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 311 open to participants now, 465 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
242nd of 1,907
130 · median 35
Started
2022
with 80 others
Phase 1
772 of 2,137
130 open now
Primary completion
2026-11
later than 103 of 463 live
Registered
1,849th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 242nd largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 81 that started in 2022, is one of 772 in phase 1, reaches primary completion later than 103 of the 463 other live ones, and was the 1,849th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

311 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

306 more — sign in →

All 311 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024.

Participants will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are met. Response assessments will be performed after Cycle 1 and then after every even numbered cycle starting with Cycle 2 until progression or study treatment discontinuation. Participants will be checked for side effects throughout the study.

03

Conditions studied

  • Leukemia, Acute Myeloid
  • Myelodysplastic Syndromes
  • Classical Hodgkin Lymphoma
  • Leukemia, B-cell
  • Leukemia, Hairy Cell
  • Mastocytosis, Aggressive Systemic
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Chronic Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients at least 18 years of age, able to provide and willing to comply with all study procedures.
  • Participants with

    • primary or secondary acute myeloid leukemia (AML) except acute promyelocytic leukemia,
    • primary or secondary myelodysplastic syndrome (MDS) with prognostic score of >3 and \<20% bone marrow blasts,
    • classical Hodgkin lymphoma (cHL),
    • chronic myelogenous leukemia (CML),
    • b-cell acute lymphocytic leukemia (B-ALL),
    • hariy cell leukemia (HCL),
    • advanced systemic mastocytosis (ASM), or
    • blastic plasmacytoid dendritic cell neoplasm (BPDCM)
  • after or refractory to at least one and with no available potentially curative treatment option.
  • Evidence of at least 20% of malignant cells with CD123 expression.
  • (ECOG) performance status of ≤ 2.
  • of at least 12 weeks.
  • Acceptable laboratory values, and heart function.
  • Continuing side effects of prior treatment are mild
  • Women and men of must agree to use highly effective forms of throughout the study through 4 months after the last dose of MGD024.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an anti-CD123-directed agent (except patients with BPDCN, who are allowed to have received prior tagraxofusp).
  • Known involvement of central nervous system (CNS) by the disease under investigation.
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient.
  • Systemic anti-cancer therapy, therapy, or other immune suppressive drugs within 14 days of first dose
  • Vaccination with any within 4 weeks prior to first dose. Inactivated annual influenza and SARS-CoV-2 vaccination are allowed.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Escalating doses of MGD024 will be assigned based on safety and tolerability of the previous dose level.

    Drug: MGD024

Interventions

  • DrugMGD024

    MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes.

06

What researchers measure

Primary outcomes

  1. Number of severe side effects in patients receiving MGD024

    Observation of side effects determines the highest safe dose for further study

    Time frame: First 28 days of the study

  2. Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation.

    Observation of side effects determines the highest safe dose for further study

    Time frame: Throughout study participation, up to 12 months.

Secondary outcomes

  1. Mean maximum concentration

    The highest concentration of MGD024 at the end of the infusion

    Time frame: Throughout study participation, up to 12 months.

  2. Mean area under the concentration-time curve (AUC)

    Total body exposure to MGD024

    Time frame: Throughout study participation, up to 12 months.

  3. Number of participants with anti-drug antibody formation

    Number of patients who develop antibodies against MDG024

    Time frame: Throughout study participation, up to 12 months.

  4. Overall response rate

    The proportion of patients with a complete response or a partial response to treatment

    Time frame: Disease response assessment on Day 28, Day 56, then every 56 days throughout the study, up to 12 months.

  5. Complete response rate

    The proportion of patient achieving a complete response according to disease-specific criteria

    Time frame: Disease response assessment on Day 28, Day 56, then every 56 days throughout the study, up to 12 months.

  6. Median progression free survival

    The time between the first dose date to the date of first documented disease-specific progression or death from any cause

    Time frame: Disease response is assessed approximately every 56 days throughout the study, up to 12 months.Assessed from Day 1 throughout the study until individual participant discontinuation, up to 12 months. Survival from Day 1 throughout the study.

  7. Median time to response

    The time between the first dose and the date of complete or partial response.

    Time frame: Disease response is assessed approximately every 56 days throughout the study, up to 12 months.

  8. Median duration of response

    The time between the date of initial response to the date of disease-specific progression or death from any cause

    Time frame: Disease response is assessed approximately every 56 days throughout the study, up to 12 months.

  9. Overall survival

    The time between the first dose date to the date of death from any cause

    Time frame: Assessed from Day 1 throughout the study until individual participant study discontinuation, up to 12 months.

  10. Number of participants with AEs and SAEs occurring after administration of tocilizumab or etanercept for cytokine release syndrome (CRS)

    Time frame: Throughout study participation, up to 12 months.

  11. Number of participants with changes in cytokines or C-reactive protein after administration of tocilizumab or etanercept

    Time frame: Throughout study participation, up to 12 months.

  12. Outcome of CRS event in participants treated with tocilizumab or etanercept

    Time frame: Throughout study participation, up to 12 months.

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Nov 2026, 52 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 52 months is above that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 5, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05362773
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Jul 13, 2022
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Frank Perabo, MD, PhD
study director · MacroGenics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion